Compare SPHL & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPHL | ONCO |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Singapore | United States |
| Employees | 71 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.3M |
| IPO Year | 2024 | 2022 |
| Metric | SPHL | ONCO |
|---|---|---|
| Price | $2.35 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 144.8K | 53.7K |
| Earning Date | 12-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,956,226.00 | $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.31 | $1.42 |
| 52 Week High | $62.40 | $179.35 |
| Indicator | SPHL | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 27.29 |
| Support Level | $2.31 | $1.54 |
| Resistance Level | $3.20 | $1.66 |
| Average True Range (ATR) | 0.58 | 0.25 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 3.72 | 3.05 |
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.